CRISPR zaps HPV in cervical lesions: first human test begins
Disease control
Recruiting now
This early study tests a new CRISPR gene therapy (BD114) in 12 women with high-grade cervical lesions caused by HPV-16. The therapy is injected directly into the lesion to disable the virus's cancer-causing genes. The main goals are to check safety and see if the lesions clear up…
Phase: NA • Sponsor: Shanghai BDgene Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 15:33 UTC